The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'

International Journal of Cardiology

Volumn 101, Issue 2, 2005, Pages 231-235

  Devroey, Dirk ^a   Velkeniers, Brigitte ^a   Duquet, William ^a   Betz, Willem ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Antilipemic agents; Arteriosclerosis drug therapy; HDL Cholesterol; Hydroxymethylglutamyl CoA reductase inhibitors; Hypercholesterolemia; Lipoproteins

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DATA ANALYSIS; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; OUTPATIENT; PRIORITY JOURNAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLOFIBRIC ACID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 18344375478     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.03.030     Document Type: Article

References (21)

1. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317:1987;1237-1245
2. Wilson P.W., Abbott R.D., Castelli W.P. High-density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 8:1988;737-741
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
5. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307
6. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622
7. Sever P.S., Dahlöf P., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
8. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22
9. Devroey D., Betz W., Coigniez P., et al. A 'Bad HDL-C responder' to statins. Cardiology. 97:2002;230-232
10. Devroey D., Velkeniers B., Betz W., et al. The prevalence of low levels of high-density lipoprotein cholesterol among patients treated with lipid-lowering drugs. Brit. J. Cardiol. 11:2004;50-55
11. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
12. University of Michigan Health System (UMHS) Screening and management of lipids. Guidelines for clinical care. 2000;University of Michigan, The University of Michigan Health System
13. Institute for Clinical Systems improvement (ICSI) Treatment of lipid disorders in adults. ICSI health care guidelines. 2002;Institute for Clinical Systems Improvement, Bloomington
14. Conroy R.M., Pyörälä K., Fitzgerald A.P., et al. On behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24:2003;987-1003
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502
16. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 92:2003;152-160
17. Milionis H.J., Papakostas J., Kakafika A., et al. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J. Clin. Pharmacol. 43:2003;825-830
18. Maitland-van der Zee A.H., Klungel O.H., Stricker B.H., et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis. 163:2002;213-222
19. O'Neill F.H., Patel D.D., Knight B.L., et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;832-837
20. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 140:1998;199-270
21. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:1999;410-418